The following financial update for October 2017 covers all performance and happenings from the month of September, and is based on the latest valuation date of 10/2/2017.
With how mediocre our performance has been this year, I think Andrew probably summed it up best earlier this month:
“Maybe we stop trying to outsmart a bull market” – Andrew M
|SFE Share Price||MoM Change in Price||Portfolio Value||Cash||Overall Return|
Our portfolio rebounded across the board, with Arbutus Biopharma really gapping up (more on that below). On the whole, we recouped nearly $1K in unrealized value in our holdings.
2017 Performance to Date
Yes, everything is still shit and we are really underperforming this year. However, we haven’t sucked this little since March. It’s the small wins really…
Transactions in the Period
|9/22/2017||Buy||Purchased 55 shares of OCPNY||-$1,935|
|9/26/2017||Interest||Interest on Cash Balance||$0.02|
Still playing it slow.
We did purchase Olympus Corp, which we hope will add to our success with undervalued medical instrument stocks. While there is no expectation this one will skyrocket, it hopefully can add to our upward momentum and keep our portfolio diversified.Still playing it slow.
Chart of the Month
There were positive moves across the portfolio, but this month has been all about the Arbutus Biopharma (Ticker – NASDAQ:ABUS) rally. The chart really speaks for itself.
That’s almost a 99% gain over the last 3 months! And 50% in September alone!
It seems to be bust or boom with biotech stocks, and right now the “BUS” is booming! With a solid pipeline, strong test results, and growing investor confidence, it has been well worth riding this one out. Too bad we didn’t BTFD and load up when it was trading for under $3 a share earlier this year.
We’ll conclude with a bonus “GIF of the Month”. Hell yeah ABUS!